KR20070091198A - Taurine synthesis, production and utility as a medicine - Google Patents
Taurine synthesis, production and utility as a medicine Download PDFInfo
- Publication number
- KR20070091198A KR20070091198A KR1020077016443A KR20077016443A KR20070091198A KR 20070091198 A KR20070091198 A KR 20070091198A KR 1020077016443 A KR1020077016443 A KR 1020077016443A KR 20077016443 A KR20077016443 A KR 20077016443A KR 20070091198 A KR20070091198 A KR 20070091198A
- Authority
- KR
- South Korea
- Prior art keywords
- effective
- concentrations
- taurine
- prevention
- control
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
의약medicine
포유류의 콜레스테롤의 배출을 위한 정량적으로 가장 중요한 경로는 담즙 염(담즙산의 짝염기)의 형성이다. 주요 담즙 염은 글리신 또는 타우린 접합체(conjugate)로서 합성되고, 분비된다. The quantitatively most important route for the release of cholesterol in mammals is the formation of bile salts (covalent bases of bile acids). The major bile salts are synthesized and secreted as glycine or taurine conjugates.
발명의 개시Disclosure of the Invention
타우린은 시스테인의 분해 생성물이다. 타우린(2-아미노에틸 설폰산)은 담즙의 성분이다. 이는 콜린산과 결합하여 타우로콜린산을 형성한다. 콜린산은 콜레스테롤의 신진대사의 산물이다. 콜린산의 형성은 몇몇의 수산화 및 산화 반응을 포함하는 경로를 포함한다. 모든 수용성 비타민이 이 반응에 참여한다.Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulfonic acid) is a component of bile. It combines with cholic acid to form taurocholine acid. Choline acid is the product of cholesterol metabolism. Formation of choline acid involves a pathway that involves several hydroxylation and oxidation reactions. All water soluble vitamins participate in this reaction.
타우린은 콜레스테롤 수치를 낮추고, 그리고 이 작용은 수용성 비타민의 존재에 의해 강화된다. Taurine lowers cholesterol levels, and this action is enhanced by the presence of water-soluble vitamins.
타우린은 고콜레스테롤혈증, 고트리글리세리드혈증 및 쓸개즙정체 또는 콩팥증후군 등과 같은 모든 지질 관련한 장애를 낮추는 데 효과적이고, 또한 가족성 또는 특발성 또는 후천성 지질 장애의 임의의 유형에 효과적이다. 타우린은 심장보호성이다. Taurine is effective in lowering all lipid related disorders such as hypercholesterolemia, hypertriglyceridemia and cholestasis or kidney disease, and is also effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective.
타우린은 또한 담석 처치(dissolution)에 효과적이다.Taurine is also effective in the treatment of gallstones.
타우린은 안전하고, 그리고 고 콜레스테롤, 저 밀도 지단백 또는 초저밀도 지단백을 정상화하는 데 효과적이다.Taurine is safe and effective at normalizing high cholesterol, low density lipoproteins, or ultra low density lipoproteins.
타우린은 또한 혈액 삼투압의 변화에 대항하는 뇌 세포의 안정화 및 세로토닌의 엔돌핀으로의 전환에 필수적이다. 이는 우울증, 편두통, 두통, 알츠하이머 병 및 정신질환 및 신경계질환에 효과적이다. Taurine is also essential for stabilizing brain cells against changes in blood osmotic pressure and for converting serotonin into endorphins. It is effective in depression, migraines, headaches, Alzheimer's disease and mental and nervous system diseases.
신규 아이디어New ideas
제어하는 것: 지질, 지단백, 콜레스테롤의 혈액 수준 및 고콜레스테롤혈증과 관련되는 질병, 정신질환 및 신경계질환 및 담석 처치, 이하가 단독으로 또는 조합된 것이 효과적이다:Controlling: Treatment of diseases related to lipids, lipoproteins, blood levels of cholesterol and hypercholesterolemia, mental and neurological diseases and gallstones, alone or in combination, are effective:
a. 타우린a. Taurine
b. 시스테인 및/또는 아세틸 시스테인b. Cysteine and / or acetyl cysteine
c. 모든 수용성 비타민c. All water soluble vitamins
요구되는 특허의 자세한 설명Detailed description of the required patent
a. 에틸 알코올의 설폰화 후 C2에서 치환 반응 또는 재조합 DNA 기술에 의한 2-아미노에틸 설폰산을 생성 또는 임의의 가능한 방법으로서 모든 공지된 방법에 의해, 또는 장에 기생하는 세균성 식물상(flora)의 이용을 촉진하는 프로바이오틱을 이용하여 사전에 간에서 형성된 타우로콜린산 및 타우로케노데옥시콜린산 등으로부터 타우린을 회수함으로써 제조되는 타우린. a. Production of 2-aminoethyl sulfonic acid by substitution reaction or recombinant DNA technology at C2 after sulfonation of ethyl alcohol or by any known method or by the use of bacterial flora that is parasitic in the intestine A taurine produced by recovering taurine from taurocholine acid, taurokenodeoxycholic acid, etc. previously formed in the liver using a promoting probiotic.
b. 모든 공지된 방법에 의해 제조되는 아세틸 시스테인.b. Acetyl cysteine prepared by all known methods.
c. 모든 공지된 방법에 의해 제조되는 수용성 비타민.c. Water soluble vitamins prepared by all known methods.
여기에서:From here:
ⅰ. "a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a", "b" 및 "c"는 효과적이다. Iii. If given as "a" or "b" or "c", or as "a + b" or "a + c" or "b + c" or "a + b + c", all "a", "b "And" c "are effective.
ⅱ. 경구 또는 비경구 또는 국부성 제제로 제공될 때, "a" 또는 "b" 또는 "c"로서, 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"로서 주어진다면, 모든 "a" 또는 "b" 및 "c"는 효과적이다.Ii. When provided in oral or parenteral or topical formulations, as "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + If given as "c", all "a" or "b" and "c" are effective.
ⅲ. "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"의 모든 그리고 임의의 조성물 및 임의의 그리고 모든 농도가 효과적이다.Iii. all and any composition and any and all concentrations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” Is effective.
ⅳ. 이용되는 타우린은 이의 산 형태 또는 산 염 또는 알칼리 염 또는 임의의 이의 화합물 또는 형태로 나타난다.Iii. The taurine used is represented in its acid form or in acid or alkali salts or in any compound or form thereof.
ⅴ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 아테롬성 경화증 및 심장질환의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" means atherosclerosis and Effective for the prevention and control of heart disease.
ⅵ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 모든 고콜레스테롤혈증, 고트리글리세리드혈증 및 모든 그리고 임의의 지질 및 지단백 장애의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” are all high cholesterol It is effective in the prevention and control of hypertension, hypertriglyceridemia and all and any lipid and lipoprotein disorders.
ⅶ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 임의의 병인론의 쓸개즙정체의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" is any etiology It is effective in the prevention and control of cholestasis of bile.
ⅷ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 간의 지방증 및 임의의 병인론의 지방간염 장애의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” is a fatty steatosis and It is effective in the prevention and control of hepatitis disorders of any etiology.
ⅸ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 담석 질환의 예방, 처치 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of "a" or "b" or "c", or "a + b" or "a + c" or "b + c" or "a + b + c" may be used for gallstone disease Effective for prevention, treatment and control.
ⅹ. 임의의 그리고 모든 농도 및 조합의 "a" 또는 "b" 또는 "c", 또는 "a+b" 또는 "a+c" 또는 "b+c" 또는 "a+b+c"는 모든 정신질환 및 모든 신경계질환의 예방 및 제어에 효과적이다.Iii. Any and all concentrations and combinations of “a” or “b” or “c”, or “a + b” or “a + c” or “b + c” or “a + b + c” are all mental disorders And effective in the prevention and control of all neurological diseases.
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EG2005010013 | 2005-01-05 | ||
EG2005010013 | 2005-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20070091198A true KR20070091198A (en) | 2007-09-07 |
Family
ID=36647837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077016443A KR20070091198A (en) | 2005-01-05 | 2005-12-31 | Taurine synthesis, production and utility as a medicine |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1844006A2 (en) |
JP (1) | JP2008526789A (en) |
KR (1) | KR20070091198A (en) |
CN (1) | CN101146767A (en) |
AP (1) | AP2007004084A0 (en) |
AU (1) | AU2005324199A1 (en) |
BR (1) | BRPI0519606A2 (en) |
CA (1) | CA2593563A1 (en) |
EA (1) | EA200701434A1 (en) |
IL (1) | IL184221A0 (en) |
MA (1) | MA29238B1 (en) |
MX (1) | MX2007008196A (en) |
NO (1) | NO20074937A (en) |
TN (1) | TNSN07226A1 (en) |
WO (1) | WO2006072259A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101932238B (en) | 2007-11-30 | 2015-04-08 | 加利福尼亚大学董事会 | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products |
CN103382170B (en) * | 2012-10-25 | 2015-04-08 | 潜江永安药业股份有限公司 | Preparation method for taurine |
CN106728405A (en) * | 2016-11-15 | 2017-05-31 | 陈思文 | A kind of taurine and water soluble tea polyphenol compound and preparation method and application |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58140017A (en) * | 1981-12-22 | 1983-08-19 | Junichi Azuma | Remedy for cardiac insufficiency |
JPH08208464A (en) * | 1994-12-02 | 1996-08-13 | Taisho Pharmaceut Co Ltd | Agent for treatment and prevention of hyperlipemia |
US6184227B1 (en) * | 1995-07-21 | 2001-02-06 | Savvipharm Inc. | Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases |
SE9601395D0 (en) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 1 |
GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
NZ527924A (en) * | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
AU8003800A (en) * | 1999-10-08 | 2001-04-23 | Joyce Corinne Bechthold | Methods and compositions for treating neurobehavioral disorders |
CN1340502A (en) * | 2000-06-30 | 2002-03-20 | 张永春 | Process for preparing taurine zinc |
CN1268733C (en) * | 2004-07-20 | 2006-08-09 | 刘辉 | Taurine functional beer and its producing process |
-
2005
- 2005-12-31 AP AP2007004084A patent/AP2007004084A0/en unknown
- 2005-12-31 KR KR1020077016443A patent/KR20070091198A/en not_active Application Discontinuation
- 2005-12-31 JP JP2007549796A patent/JP2008526789A/en active Pending
- 2005-12-31 WO PCT/EG2005/000044 patent/WO2006072259A2/en active Application Filing
- 2005-12-31 AU AU2005324199A patent/AU2005324199A1/en not_active Abandoned
- 2005-12-31 EP EP05818935A patent/EP1844006A2/en not_active Withdrawn
- 2005-12-31 EA EA200701434A patent/EA200701434A1/en unknown
- 2005-12-31 BR BRPI0519606-0A patent/BRPI0519606A2/en not_active IP Right Cessation
- 2005-12-31 CN CNA2005800460663A patent/CN101146767A/en active Pending
- 2005-12-31 CA CA002593563A patent/CA2593563A1/en not_active Abandoned
- 2005-12-31 MX MX2007008196A patent/MX2007008196A/en not_active Application Discontinuation
-
2007
- 2007-06-14 TN TNP2007000226A patent/TNSN07226A1/en unknown
- 2007-06-26 IL IL184221A patent/IL184221A0/en unknown
- 2007-07-26 MA MA30110A patent/MA29238B1/en unknown
- 2007-09-28 NO NO20074937A patent/NO20074937A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005324199A1 (en) | 2006-07-13 |
WO2006072259A2 (en) | 2006-07-13 |
MA29238B1 (en) | 2008-02-01 |
TNSN07226A1 (en) | 2008-11-21 |
CN101146767A (en) | 2008-03-19 |
WO2006072259A3 (en) | 2007-10-04 |
JP2008526789A (en) | 2008-07-24 |
MX2007008196A (en) | 2008-02-22 |
AP2007004084A0 (en) | 2007-08-31 |
IL184221A0 (en) | 2008-12-29 |
NO20074937A (en) | 2007-09-28 |
EA200701434A1 (en) | 2008-10-30 |
EP1844006A2 (en) | 2007-10-17 |
BRPI0519606A2 (en) | 2009-02-25 |
CA2593563A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2256472T3 (en) | NATURAL PHENOLIC PRODUCTS AND DERIVED FROM THEM FOR THE PROTECTION AGAINST NEURODEGENERATIVE DISEASES. | |
CN101307088B (en) | Method for preparing cholic acid conjugates | |
US9301931B2 (en) | Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis | |
TW589186B (en) | Ascorbyl-phosphoryl-cholesterol | |
EP0703954B1 (en) | Polyphenol derivative compositions and preparation thereof | |
JPH11504914A (en) | 1,3-propanediol derivatives as biologically active compounds | |
CN104395273A (en) | Prodrugs of vitamine K | |
ITFI20070224A1 (en) | NEW S-ACYL SURFACES OF GLUTATHY, THEIR SYNTHESIS AND USE IN THE TREATMENT OF PATHOLOGIES RELATED TO THE CELL OXIDATIVE STRESS | |
FR2873376A1 (en) | NOVEL SELENO-HYDROXYACIDS AND DERIVATIVES, NUTRITION APPLICATIONS, COSMETICS AND PHARMACY | |
KR20090112631A (en) | Novel lipid compounds | |
KR20070091198A (en) | Taurine synthesis, production and utility as a medicine | |
CA2633225C (en) | Novel polyunsaturated compounds, method for preparing same and compositions containing same | |
BRPI0611316B1 (en) | processes for the preparation, separation or purification of phosphatidylserine | |
FR2704753A1 (en) | Use of derivatives of 4-thio resorcin or 4-thio 1-3-dihydroxybenzene, in cosmetic or dermopharmaceutical compositions with depigmenting action. | |
JP7073384B2 (en) | Compounds and usage | |
JP4226324B2 (en) | Carboxylic acid type lipid | |
WO2011030727A1 (en) | External preparation containing pantethine phosphate ester | |
JP2008504231A (en) | Oxidized dibenzo-alpha-pyrone chromoprotein | |
JP2011241164A5 (en) | ||
AU766045B2 (en) | Phospholipid derivatives of non-steroidal anti-inflammatory drugs | |
JP2021508732A (en) | Glucosamine derivatives to prevent or treat joint disorders | |
CN107759553A (en) | New flavonoids and application thereof | |
JP4861753B2 (en) | Skin external composition | |
CN112888419A (en) | Compositions and methods for treating and preventing Leber's hereditary optic neuropathy | |
WO2021187314A1 (en) | Mitochondrial dysfunction improving agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |